Navigation Links
SuperGen Reports 2007 Fourth Quarter and Annual Financial Results
Date:3/3/2008

I-EORTC

International Conference, the Company announced the following: MP470, a

clinical-stage multi-targeted tyrosine kinase inhibitor, demonstrates

preclinical synergy with DNA damaging agents (Poster A173, Abstract

1026); S110, a decitabine-derived DNA demethylating agent, shows

improved pre-clinical activity due to increased drug delivery and

stability (Poster 140, Abstract 1038); and, the proprietary CLIMB(TM)

technology was successful in the lead development and design of small

molecule JAK2 and Pim kinase inhibitors (Posters C200, Abstract 907 and

C208, Abstract 985). Also, Dr. Peter A. Jones, Director of USC's Norris

Cancer Center, further discussed S110 in a plenary session on cancer

epigenetics.

-- The Company announced during an oral presentation at the American

Society for Therapeutic Radiology and Oncology's 49th Annual Meeting in

Los Angeles that MP470, a clinical-stage multi-targeted tyrosine kinase

inhibitor, is cytotoxic to glioblastoma multiforme cell lines (Abstract

178). Activity was also demonstrated in vivo in a glioblastoma

multiforme xenograft model. Evidence presented suggests that MP470

inhibits DNA damage repair through suppression of a critical DNA repair

protein, Rad51. Dr. James Welsh of the University of Arizona, who

conducted these pre-clinical studies, also revealed that the pre-

clinical activity of MP470 against glioblastoma multiforme cells is

synergistic with radiation.

December 2007:

-- As part of a series of presentations at the American Society of

Hematology's 49th Annual Meeting, the Company described how its

proprietary CLIMB technology was used in lead development and design of

small molecule Pim kinase inhibitors (Poster 845, Abstract 2655) and

how its novel decitabine dinucleotide
'/>"/>

SOURCE SuperGen Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. SuperGen to Announce 2007 Fourth Quarter and Fiscal Year-End Financial Results March 3, 2008
2. SuperGen to Present at Thomas Weisel Partners Healthcare Conference September 5th
3. Dr. Audrey F. Jakubowski of SuperGen Retires as Chief Regulatory and Quality Officer
4. Stereotaxis Reports Fourth Quarter and Full Year 2007 Financial Results
5. Genetic Engineering & Biotechnology News reports on advances in miRNA
6. Rosetta Genomics Reports Fourth-Quarter and Full-Year 2007 Financial Results
7. Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007
8. Cepheid Reports Fourth Quarter and Full Year 2007 Results
9. Strategic Diagnostics Reports Fourth Quarter and Full-Year Financial Results
10. US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results
11. Barr Reports GAAP Earnings of $1.18 Per Share for 2007 and $0.30 Per Share for the Fourth Quarter; Adjusted Earnings Were $3.16 Per Share for 2007 and $0.79 Per Share for the Fourth Quarter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... zFlo Motion , a US leader in biomechanics ... from a new partner. STT-Systems has developed an ... years, with offerings in the optical-motion capture, 3D scanning, and ... measurement unit), iSen, is opening eyes around the world. With ...
(Date:1/22/2015)... Denville, NJ (PRWEB) January 22, 2015 ... shearing technologies such as the Bioruptor® and complete ... semi-automation system for chromatin immunoprecipitation, alleviating the need ... reagents and controls needed for ChIP of histones ...
(Date:1/22/2015)... 2015   GenoSpace , a precision medicine software company that ... broad use of genomic, imaging and other biomedical data in ... Michelle Munson , CEO of Aspera, an IBM Company, to ... http://photos.prnewswire.com/prnh/20150122/170713 "We are pleased to ...
(Date:12/24/2014)... and NEW YORK , Dec. 24, 2014 ... advancing patient care in critical areas, announced the closing of ... and warrants to purchase up to an aggregate 3,500,000 shares ... share and $.01 per warrant.  The warrants have a per ...
Breaking Biology Technology:3D Motion Capture Just Got Easy 2Diagenode Launches Unique Semi-Automated Solution for Chromatin Immunoprecipitation 2GenoSpace Expands Board with Appointment of Michelle Munson 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3
... today announced that the U.S. Food and Drug Administration (FDA) has approved a five-day dosing regimen for Dacogen® (decitabine) for Injection to treat patients with myelodysplastic ... ... , ... ...
... , March 11 Stem Cell Assurance, ... to announce the inclusion of one of the Cleveland Clinic,s ... F.A.C.S.  Dr. Ross will officially take up Vice Chairmanship for ... welcomes his appointment to strengthen operations of their national physician ...
... ... , ... (PRWEB) March 11, 2010 -- ClearTrial, the leading provider of Clinical Trial Operations (CTO) ... Deutsche Bank and Cowen & Company at CBI,s 2010 Accounting and Reporting Congress in ...
Cached Biology Technology:FDA Approves Five-Day Dosing Regimen for Dacogen(R) (decitabine) for Injection, Offering a New Outpatient Dosing Option for Myelodysplastic Syndromes (MDS) 2FDA Approves Five-Day Dosing Regimen for Dacogen(R) (decitabine) for Injection, Offering a New Outpatient Dosing Option for Myelodysplastic Syndromes (MDS) 3FDA Approves Five-Day Dosing Regimen for Dacogen(R) (decitabine) for Injection, Offering a New Outpatient Dosing Option for Myelodysplastic Syndromes (MDS) 4FDA Approves Five-Day Dosing Regimen for Dacogen(R) (decitabine) for Injection, Offering a New Outpatient Dosing Option for Myelodysplastic Syndromes (MDS) 5FDA Approves Five-Day Dosing Regimen for Dacogen(R) (decitabine) for Injection, Offering a New Outpatient Dosing Option for Myelodysplastic Syndromes (MDS) 6FDA Approves Five-Day Dosing Regimen for Dacogen(R) (decitabine) for Injection, Offering a New Outpatient Dosing Option for Myelodysplastic Syndromes (MDS) 7FDA Approves Five-Day Dosing Regimen for Dacogen(R) (decitabine) for Injection, Offering a New Outpatient Dosing Option for Myelodysplastic Syndromes (MDS) 8Joseph J. Ross, M.D., F.A.C.S. Joins Stem Cell Assurance as Vice Chairman 2Joseph J. Ross, M.D., F.A.C.S. Joins Stem Cell Assurance as Vice Chairman 3Joseph J. Ross, M.D., F.A.C.S. Joins Stem Cell Assurance as Vice Chairman 4ClearTrial to Head Panel of Leading Wall Street Analysts at Pharmaceutical Accounting and Reporting Congress 2ClearTrial to Head Panel of Leading Wall Street Analysts at Pharmaceutical Accounting and Reporting Congress 3
(Date:12/22/2014)... Research and Markets ( http://www.researchandmarkets.com/research/fx4bg3/the_global ) ... Global Watermarking and Fingerprinting Markets" report to ... This insight provides an overview ... markets. Watermarking aims to control and monitor piracy ...
(Date:12/19/2014)... , Dec. 18, 2014 Research and Markets ( ... Market Monitor: North America Perimeter Security Systems Market" report ... The North American perimeter security market is estimated ... 2019. Although the U.S. market holds a larger share in ...
(Date:12/17/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/s6qzt5/samsung_galaxy_s5 ) ... S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis" ... http://photos.prnewswire.com/prnh/20130307/600769 Based on a totally ... for the first time a fingerprint sensor in its ...
Breaking Biology News(10 mins):The Global Watermarking and Fingerprinting Markets 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 3Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2
... means that they must be continually replaced by calling ... types needed by the body. Claus Nerlov and ... unit in Monterotondo, Italy, in collaboration with researchers from ... in Sweden, have now uncovered how an intracellular communication ...
... the simplest life forms on our planet, consisting of only ... and archebacteria), viruses are the second most common type of ... form. In order to gain a better understanding of the ... would be highly useful to be able to determine their ...
... The function of horned beetles' wild protrusions has been ... plausible; combat and mate selection, more likely. Even Charles ... one imagines with some frustration -- the horns were ... (Dec. 2006) and the Nov. 2006 issue of Evolution, ...
Cached Biology News:Lost in the labyrinth 2Weighty viruses 2Vanishing beetle horns have surprise function 2Vanishing beetle horns have surprise function 3
... The Corning CellBIND surface is produced by ... more hydrophilic surface giving more consistent, even ... CellBIND enhances cell attachment and growth uunder ... medium. • CellBIND may provide a more ...
...
Mouse monoclonal antibody raised against a partial recombinant ARHGEF11. NCBI Entrez Gene ID = ARHGEF11...
... Channel Cell Lines ,High Quality, Functionally-Validated, Ion ... well known for having a critical role ... have a key function in pain, CNS ... channels have been investigated in therapeutic areas, ...
Biology Products: